Table 3 Effect of SVR on the incidence of SLE or RA in different subgroups.

From: Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis

Variable

Conditions

Non-SVR (%)

SVR (%)

Crude HR (95% CI)

p value

Age (years)

<55

0.16

0.32

2.25 (0.69–7.36)

0.182

≥55

0.15

0.11

0.73 (0.15–3.63)

0.700

Sex

Male

0.07

0.20

3.01 (0.68–13.39)

0.149

Female

0.25

0.19

0.82 (0.23–2.93)

0.763

BMI (kg/m2)

<24

0.24

0.41

1.88 (0.56–6.34)

0.307

≥24

0.11

0.10

0.91 (0.19–4.41)

0.907

AST (U/L)

<80

0.15

0.12

0.89 (0.19–4.22)

0.883

≥80

0.16

0.30

1.85 (0.54–6.35)

0.326

ALT (U/L)

<80

0.16

0.09

0.64 (0.07–5.61)

0.686

≥80

0.15

0.26

1.79 (0.61–5.23)

0.291

eGFR (mL/min/1.73m2)

≥60

0.15

0.21

1.49 (0.57–3.89)

0.412

<60

0.25

0

NA

NA

Liver cirrhosis

No

0.17

0.17

1.10 (0.31–3.90)

0.885

Yes

0.24

0.14

0.61 (0.06–6.16)

0.675

HCV RNA (IU/mL)

≤400,000

0.16

0

NA

NA

>400,000

0.10

0.20

2.07 (0.53–7.99)

0.293

HCV genotype

1

0.07

0.15

2.30 (0.46–11.45)

0.309

2

0.22

0.23

1.26 (0.28–5.67)

0.765

FIB-4

<3.25

0.15

0.21

1.45 (0.47–4.53)

0.521

≥3.25

0.15

0.18

1.31 (0.23–7.49)

0.760

DM

No

0.16

0.29

2.38 (0.66–8.51)

0.183

Yes

0.33

0

NA

NA

Hypertension

No

0.21

0.29

1.78 (0.53–5.97)

0.350

Yes

0.10

0

NA

NA

  1. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HCV, hepatitis C virus; NA, not applicable; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SVR, sustained virological response.
Back to article page